Reactome | SLC27A2 ligates CoA to bempedoic acid to form ETC-1002-CoA

SLC27A2 ligates CoA to bempedoic acid to form ETC-1002-CoA

Stable Identifier

R-HSA-9734535

Type

Reaction [transition]

Species

Homo sapiens

Compartment

cytosol

ReviewStatus

5/5

Locations in the PathwayBrowser

Expand all

General

SBML | | PDF

SVG | | PPTX | SBGN

SLC27A2 ligates CoA to bempedoic acid to form ETC-1002-CoA

Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

Bempedoic acid (ETC-1002) is first-in-class ATP-citrate lyase (ACLY) inhibitor used once a day for reducing LDL cholesterol levels in statin-refractory patients. ETC-1002 itself is a prodrug, which is converted to the active metabolite ETC-1002–CoA by endogenous liver acyl-CoA synthetase (SLC27A2, ACSVL1) activity (Pinkosky et al. 2016).

Literature References

PubMed ID	Title	Journal	Year
27892461	Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis Steinberg, GR, Pinkosky, SL, Day, EA, Newton, RS, Smith, BK, Birch, CM, Lhotak, S, Austin, RC, Filippov, S, Lalwani, ND, Groot, PHE, Ford, RJ	Nat Commun	2016